[18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis.
Antonio CarotenutoBeniamino GiordanoGeorge DervenoulasHeather WilsonMattia VeroneseZachary ChappellSotirios PolychronisGennaro PaganoJane MackewnFederico E TurkheimerSteven C R WilliamsAlexander HammersEli SilberPeter BrexMarios PolitisPublished in: European journal of nuclear medicine and molecular imaging (2019)
Our findings demonstrate that [18F]florbetapir PET imaging can measure in-vivo myelin damage in patients with MS. Demyelination in MS is not restricted to lesions detected through conventional MRI but also involves the normal appearing white matter. Although longitudinal studies are needed, [18F]florbetapir PET imaging may have a role in clinical settings in the management of MS patients.
Keyphrases
- pet imaging
- multiple sclerosis
- white matter
- mass spectrometry
- positron emission tomography
- ms ms
- end stage renal disease
- contrast enhanced
- chronic kidney disease
- ejection fraction
- magnetic resonance imaging
- newly diagnosed
- computed tomography
- prognostic factors
- magnetic resonance
- patient reported outcomes
- cross sectional
- pet ct
- diffusion weighted imaging